Replies to post #19383 on Ariad Pharmaceuticals Inc fka ARIA

[micanwait]

I suspect that most oncologists will have the same opinion as Dr. Cortes --- the most likely best outcome will come from using the most likely best drug.

The health insurers may not like it, but the medical liability insurers may have a different point of view.

I still think that the possible loss of the huge Gleevec income stream is a huge incentive for Novartis to explore acquiring Ariad.